IL132354A0 - Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis - Google Patents

Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis

Info

Publication number
IL132354A0
IL132354A0 IL13235498A IL13235498A IL132354A0 IL 132354 A0 IL132354 A0 IL 132354A0 IL 13235498 A IL13235498 A IL 13235498A IL 13235498 A IL13235498 A IL 13235498A IL 132354 A0 IL132354 A0 IL 132354A0
Authority
IL
Israel
Prior art keywords
treatment
matrix protein
rheumatoid arthritis
oligomeric matrix
cartilage oligomeric
Prior art date
Application number
IL13235498A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL132354A0 publication Critical patent/IL132354A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13235498A 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis IL132354A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701409A SE9701409D0 (sv) 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis
PCT/SE1998/000682 WO1998046253A1 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
IL132354A0 true IL132354A0 (en) 2001-03-19

Family

ID=20406587

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13235498A IL132354A0 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis

Country Status (21)

Country Link
EP (1) EP1019078B1 (xx)
JP (1) JP2001520647A (xx)
KR (1) KR20010006352A (xx)
CN (1) CN1260721A (xx)
AT (1) ATE245438T1 (xx)
AU (1) AU746221B2 (xx)
BR (1) BR9808591A (xx)
CA (1) CA2286791A1 (xx)
DE (1) DE69816634T2 (xx)
EE (1) EE9900464A (xx)
HU (1) HUP0002231A3 (xx)
ID (1) ID24561A (xx)
IL (1) IL132354A0 (xx)
IS (1) IS5210A (xx)
NO (1) NO995004D0 (xx)
NZ (1) NZ338084A (xx)
PL (1) PL336163A1 (xx)
SE (1) SE9701409D0 (xx)
SK (1) SK141399A3 (xx)
TR (1) TR199902564T2 (xx)
WO (1) WO1998046253A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849594B1 (en) * 1999-06-30 2005-02-01 John Lawler Purification and use of human recombinant cartilage oligomeric matrix protein
SE9904236D0 (sv) 1999-11-22 1999-11-22 Ana Mar Diagnostics Ab Immunoassay
KR100429288B1 (ko) * 2001-11-23 2004-04-29 장오기계 주식회사 전사인쇄장치
CN100417415C (zh) * 2006-06-28 2008-09-10 文彦春 浸润治疗关节炎的药物
WO2014003679A1 (en) 2012-06-28 2014-01-03 Anamar Ab Determining pathological cartilage turnover

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5872094A (en) * 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface

Also Published As

Publication number Publication date
NO995004L (no) 1999-10-14
SE9701409D0 (sv) 1997-04-15
EE9900464A (et) 2000-04-17
SK141399A3 (en) 2000-08-14
BR9808591A (pt) 2000-05-23
ID24561A (id) 2000-07-27
WO1998046253A1 (en) 1998-10-22
ATE245438T1 (de) 2003-08-15
DE69816634T2 (de) 2004-06-03
NZ338084A (en) 2001-07-27
IS5210A (is) 1999-10-12
EP1019078B1 (en) 2003-07-23
CN1260721A (zh) 2000-07-19
HUP0002231A2 (hu) 2000-11-28
AU746221B2 (en) 2002-04-18
KR20010006352A (ko) 2001-01-26
HUP0002231A3 (en) 2002-09-30
JP2001520647A (ja) 2001-10-30
PL336163A1 (en) 2000-06-05
CA2286791A1 (en) 1998-10-22
EP1019078A1 (en) 2000-07-19
DE69816634D1 (de) 2003-08-28
NO995004D0 (no) 1999-10-14
TR199902564T2 (xx) 2000-02-21
AU7093898A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
NO20006718L (no) Proteaseinhibitorer
HK1049103A1 (zh) 含有利托那韋(abt-538)並與茚地那韋(mk-639)結合藥物的組合物以及他們在治療艾滋病中的用途
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AP2001002062A0 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
MY104129A (en) Treatment of arthritis.
IL132354A0 (en) Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
IL123001A0 (en) Analgesic from snake venom
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
GR3033698T3 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
HK1019770A1 (en) Il-6 mutein
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".
RU98109728A (ru) Способ лечения и профилактики заболеваний рыб
UA30874A (uk) Спосіб профілактики полігіпомікроелементозу
MX9800686A (es) Nueva proteina hmw humana mp52s.
UA34211A (uk) Спосіб репозиції зміщеного досередини малого відламку під час перелому суглобового відросту нижньої щелепи
UA29236A (uk) Спосіб лікування пізніх гестозів
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь